![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
1 National Institute of Mental Health, Addiction Research Center, U. S. Public Health Service Hospital, Lexington, Kentucky
Using a variety of subjective and objective measures, the relative potency of heroin to morphine administered intravenously to postaddicts found 1.80 to 2.66 mg of morphine sulfate equal to 1 mg of heroin. In addition, it was found that postaddicts could identify heroin and morphine as such with a high degree of accuracy when these agents were administered intravenously either on an acute or chronic basis. Though postaddicts showed no preference for one or the other of these drugs when administered on a single injection basis, five out of eight expressed a preference for heroin in the short-term addiction study. However, on the basis of postaddicts' reports on "the most important effects of morphine and heroin," no constellation of effects could be discerned that explained the preference for heroin. Equipotent doses of these drugs had quite comparable action time courses when administered intravenously, and on this basis there was no marked difference in their ability to produce feelings of "euphoria," ambition, nervousness, relaxation, drowsiness, or sleepiness. Although the heroin abstinence syndrome was of shorter duration than that of morphine, the peak intensity was quite comparable for the two drugs. Data acquired during short-term addiction studies did not support the statement that tolerance develops more rapidly to heroin than to morphine. These findings have been discussed in relation to the physicochemical properties of heroin and morphine and the metabolism of heroin.
Submitted on February 20, 1961
This article has been cited by other articles:
|
|
 |
|
  T. B. Saurer, S. G. Ijames, and D. T. Lysle Evidence for the Nucleus Accumbens as a Neural Substrate of Heroin-Induced Immune Alterations J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1040 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-X. Pan, J. Xu, M. Xu, G. C. Rossi, J. E. Matulonis, and G. W. Pasternak Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions PNAS, March 24, 2009; 106(12): 4917 - 4922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Rady, B. B. Holmes, P. S. Portoghese, and J. M. Fujimoto Morphine Tolerance in Mice Changes Response of Heroin from {micro} to {delta} Opioid Receptors Experimental Biology and Medicine, June 1, 2000; 224(2): 93 - 101. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. R. Cohen, R. M. Cohen, D. Pickar, H. Weingartner, and D. L. Murphy High-Dose Naloxone Infusions in Normals: Dose-Dependent Behavioral, Hormonal, and Physiological Responses Arch Gen Psychiatry, June 1, 1983; 40(6): 613 - 619. [Abstract] [PDF]
|
|
|
|
|
|
C. Kornetsky, R. U. Esposito, S. McLean, and J. O. Jacobson Intracranial Self-stimulation Thresholds: A Model for the Hedonic Effects of Drugs of Abuse Arch Gen Psychiatry, March 1, 1979; 36(3): 289 - 292. [Abstract] [PDF]
|
|
|
|
|
|
D. R. Jasinski, J. S. Pevnick, and J. D. Griffith Human Pharmacology and Abuse Potential of the Analgesic Buprenorphine: A Potential Agent for Treating Narcotic Addiction Arch Gen Psychiatry, April 1, 1978; 35(4): 501 - 516. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Jasinski, J. Nutt, C. Haertzen, J. Griffith, and W. Bunney Lithium: effects on subjective functioning and morphine-induced euphoria Science, February 11, 1977; 195(4278): 582 - 584. [Abstract] [PDF]
|
|
|
|
|
|
D. R. Jasinski, J. S. Pevnick, S. C. Clark, and J. D. Griffith Therapeutic Usefulness of Propoxyphene Napsylate in Narcotic Addiction Arch Gen Psychiatry, February 1, 1977; 34(2): 227 - 233. [Abstract] [PDF]
|
|
|
|
|
|
S. M. Mirin, R. E. Meyer, and H. B. McNamee Psychopathology and Mood During Heroin Use: Acute vs Chronic Effects Arch Gen Psychiatry, December 1, 1976; 33(12): 1503 - 1508. [Abstract] [PDF]
|
|
|
|
|
|
A. Goldstein Heroin Addiction: Sequential Treatment Employing Pharmacologic Supports Arch Gen Psychiatry, March 1, 1976; 33(3): 353 - 358. [Abstract] [PDF]
|
|
|
|
|
|
J. Volavka, R. Levine, S. Feldstein, and M. Fink Short-Term Effects of Heroin in Man: Is EEG Related to Behavior? Arch Gen Psychiatry, May 1, 1974; 30(5): 677 - 681. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
